Drugs in Dev. Nephrology
Phase I/ Phase II
Germany 
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eleva Doses Factor H Therapy In C3-Glomerulopathy To Healthy Volunteers
Details : The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G).
Product Name : CPV-104
Product Type : Protein
Upfront Cash : Inapplicable
February 07, 2024
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Felzartamab
Therapeutic Area : Nephrology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures
Details : Enrollment/screening of patients in the M-PLACE study with MOR202 is temporarily paused. This could lead to delays in previously communicated timelines.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Felzartamab
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
